Phaseline

Targets › SOD2

SOD2 (Superoxide dismutase [Mn], mitochondrial): drug programs, companies and trials

3 programs from 3 companies in 3 trials: 2 Phase 2, 1 Phase 1; Oncology; next expected readout Jan 2027.

Destroys superoxide anion radicals which are normally produced within the cells and which are toxic to biological systems. (UniProt, P04179)

Open in Phaseline: the race on SOD2, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
NRG OncologyMnSOD Mimetic BMX-001
Manganese superoxide dismutase (SOD2) mimetic; neutralizes free radicals and reactive oxyg
SOD2Phase 2Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8Jan 2027
West China Hospitalsuperoxide dismutase skin spray
antioxidant enzyme that catalyzes the dismutation of superoxide radicals
SOD1, SOD2, SOD3Phase 2Radiation-induced DermatitisJan 2027
The University of Texas Health Science Center at San AntonioAvasopasem
Mitochondrial superoxide dismutase (SOD2) mimetic; superoxide scavenger
SOD2Phase 1Breast Cancer MetastaticOct 2027

Conditions

Radiation-induced Dermatitis (1) Breast Cancer Metastatic (1) Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 (1)

Modalities

small molecule (2), protein or peptide (1)

Companies

West China Hospital (1) The University of Texas Health Science Center at San Antonio (1) NRG Oncology (1)

Related targets

SOD1 (1) SOD3 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.